Table 2.
The changes of percutaneous transluminal pulmonary angioplasty for TA patients with PH.
| Variables | Preoperative (n = 32) | Follow up (n = 30) | P |
|---|---|---|---|
| Clinical changes | |||
| WHO functional class, I/II/III/IV | 0/15/16/1 | 12/18/0/0 | <0.001 |
| 6MWD, m | 441.6 ± 59.1 | 517.0 ± 40.4 | <0.001 |
| Blood test | |||
| CRP, mg/l | 5.6 ± 7.5 | 4.8 ± 4.0 | 0.510 |
| ESR, mm/h | 5 (3, 8.5) | 6.5 (4.8, 10.0) | 0.258 |
| TBIL, mmol/L | 19.6 ± 12.2 | 12.6 ± 6.3 | <0.001 |
| NTpro-BNP, pg/mL | 344.0 (177.5, 2144.5) | 170.5 (98.5, 488.6) | <0.001 |
| ECHO | |||
| RVD, mm | 29.5 ± 7.2 | 27.0 ± 6.7 | 0.016 |
| LVD, mm | 39.0 ± 5.8 | 42.4 ± 4.5 | <0.001 |
| TAPSE, mm | 17.2 ± 2.9 | 19.4 ± 2.6 | <0.001 |
| PASP, mm Hg | 79.2 ± 26.3 | 62.0 ± 21.7 | 0.005 |
| RHC | |||
| Mean PAP, mm Hg | 49.7 ± 12.7 | 37.9 ± 9.6 | <0.001 |
| PVR, Wood units | 10.1 ± 5.7 | 6.0 ± 2.3 | <0.001 |
| CI, l/min/m | 2.58 ± 0.72 | 2.96 ± 0.72 | 0.011 |
| PAWP, mm Hg | 10.9 ± 1.6 | 10.7 ± 2.0 | 0.674 |
Data are presented as the means ± SD, Median or as numbers and percentages; TA, takayasu’s arteritis; PH, pulmonary hypertension; 6MWD, 6-minute walk distance; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; TBIL, total bilirubin; RVD, right ventricular diameter; LVD, left ventricular diameter; TAPSE, tricuspid annular plane systolic excursion; PASP, pulmonary artery systolic pressure; RHC, right heart catheterization; PVR, pulmonary vascular resistance; CI, cardiac index; PAWP, pulmonary arterial wedge pressure.